Yong-Xu Wang receives NIH grant to explore new therapeutic agent for liver disease

Yong-Xu Wang, PhD, has received NIH funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to investigate a new approach for resolution of nonalcoholic fatty liver and nonalcoholic steatohepatitis by a novel adipokine. Nonalcoholic steatohepatitis (NASH) is a type of liver disease caused by the accumulation of fat in the organ, and can lead to cirrhosis, liver failure and cancer. The grant will determine whether an adipose-enriched cytokine identified by Dr. Wang’s group can improve NASH symptoms in mouse models of the disease, and will investigate the cytokine’s mechanism-of-action.